{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(6)"],"submitter":["Antill Y"],"funding":["AstraZeneca"],"pubmed_abstract":["<h4>Background</h4>In this study, we assessed the activity of durvalumab, an antibody to programmed death ligand-1, in two cohorts of women with advanced endometrial cancers (AEC)-mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR).<h4>Methods</h4>A multicenter phase two study was performed in women with AEC with pMMR tumor progressing after one to three lines of chemotherapy and women with AEC with dMMR tumor progressing after zero to three lines of chemotherapy. Mismatch repair status was based on immunohistochemistry expression. All women received durvalumab 1500 mg given every 4 weeks until progression or unacceptable toxicity. The primary endpoint was objective tumor response by RECIST V.1.1 modified for immune-based therapeutics.<h4>Results</h4>Seventy-one women we"],"journal":["Journal for immunotherapy of cancer"],"pagination":["e002255"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8190057"],"repository":["biostudies-literature"],"pubmed_title":["Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial."],"pmcid":["PMC8190057"],"pubmed_authors":["Yip S","Smith D","Lombard J","Mileshkin L","Spurdle A","Coward J","Robledo K","Lee YC","Andrews J","Meniawy T","Friedlander M","Shannon C","Kok PS","Australia New Zealand Gynaecological Oncology Group (ANZGOG)","Goss G","Stockler MR","Baron-Hay S","Beale P","Cummins M","Antill Y","Barnes E"],"additional_accession":[]},"is_claimable":false,"name":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.","description":"<h4>Background</h4>In this study, we assessed the activity of durvalumab, an antibody to programmed death ligand-1, in two cohorts of women with advanced endometrial cancers (AEC)-mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR).<h4>Methods</h4>A multicenter phase two study was performed in women with AEC with pMMR tumor progressing after one to three lines of chemotherapy and women with AEC with dMMR tumor progressing after zero to three lines of chemotherapy. Mismatch repair status was based on immunohistochemistry expression. All women received durvalumab 1500 mg given every 4 weeks until progression or unacceptable toxicity. The primary endpoint was objective tumor response by RECIST V.1.1 modified for immune-based therapeutics.<h4>Results</h4>Seventy-one women we","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2026-06-16T03:11:21.496Z","creation":"2026-06-16T03:06:58.72Z"},"accession":"S-EPMC8190057","cross_references":{"pubmed":["34103352"],"doi":["10.1136/jitc-2020-002255"]}}